EU GMP vs. FDA GMP

A Deep Dive for Export-Ready Manufacturers

By Andrew Samann and Kate Evans, PhD · Intrepid Scientific · 2026-06-20

Companion pieces: Build Once, Build to the Highest Bar (why you build one quality system to the highest common bar) · One Pathway, Every Regulator (the method that absorbs any of these standards).

0. Read-Me-First Summary

If you manufacture a drug, an API, or — increasingly — a cannabis or botanical product destined for both the United States and the European Union, you operate under two Good Manufacturing Practice regimes at once: FDA GMP (21 CFR Parts 210 and 211, plus ICH Q7 for APIs) and EU GMP (EudraLex Volume 4). The reassuring news is that the two agree on roughly 70–80% of substance. Both demand written procedures, qualified personnel, controlled facilities, validated processes, identity-tested materials, traceable batches, investigated deviations, and recalls executable to the patient.

The expensive news is that export programs do not fail in the 80% that overlaps. They fail in the 20% that diverges — and the divergences are structural, not cosmetic:

The Qualified Person (QP). The EU requires a named, legally accountable individual to certify every batch before release. The US has no equivalent; the quality-control unit releases internally. This is the single largest structural difference between the two systems.
Principle vs. prescription. EU GMP is principle-based, elaborated through a system of annexes. FDA GMP is prescriptive, codified in the Code of Federal Regulations. The same requirement reads differently, and a control that satisfies one framing can still fail the other.
The Pharmaceutical Quality System. ICH Q10 is explicitly required in the EU; in the US it is aligned-with but not independently mandated — Part 211 plus the QC-unit construct carries the load.
Contamination control, the Site Master File, GDP, and the food/supplement carve-outs each diverge in ways that surface during a foreign inspection, not on paper.

This piece walks those differences clause by clause. It is written for the operator who has decided — or is deciding — to build for both markets, and wants to know exactly where the two rulebooks part company. The strategic conclusion is the one we argue in Build Once, Build to the Highest Bar: you do not build two quality systems. You build one system to the highest common bar, with explicit hooks for the jurisdiction-specific deltas. This document is the map of those deltas.

1. The Comparison at a Glance

Topic	EU GMP	FDA GMP (US)
Governing regulation	EudraLex Volume 4; GMP principles in Commission Directive (EU) 2017/1572 (human), Delegated Reg. (EU) 2017/1569 (investigational)	21 CFR Parts 210 & 211 (drugs); Part 111 (dietary supplements); Part 117 (food)
Regulatory body	EMA + national competent authorities (MHRA pre-Brexit lineage, BfArM, ANSM, AIFA, etc.)	U.S. Food & Drug Administration
Legal basis	EU Directives & Regulations; binding across Member States via national transposition	Federal Food, Drug & Cosmetic Act; enforced by FDA
Regulatory style	Principle-based + annex system	Prescriptive + guidance documents
Quality system	Pharmaceutical Quality System (ICH Q10) explicitly required	QC unit required (211.22); ICH Q10 aligned, not separately mandated
API manufacturing	EudraLex Vol. 4 Part II (= ICH Q7)	21 CFR 211 + ICH Q7 guidance
Validation	Annex 15; lifecycle qualification (DQ/IQ/OQ/PQ) + ongoing PV	211.68/211.100 + FDA Process Validation Guidance (2011), Stages 1–3
Sterile / contamination	Annex 1 (rev. 2022); Contamination Control Strategy mandatory	211.113 + FDA Aseptic Processing Guidance (2004); allergen controls in Part 117
Deviations / OOS	Investigated; CAPA; trending expected	OOS investigation required (211.192); CAPA expected
Supplier qualification	Audits + QP oversight; written technical/quality agreements	Vendor qualification expected (211.84); internal QC unit; no QP
Batch release	Qualified Person certifies each batch (Annex 16; Dir. 2001/83/EC Arts. 48–52)	QC unit approves/rejects internally (211.22); no QP
Inspections	National competent authorities; EU database (EudraGMDP)	FDA domestic + foreign; 483s, Warning Letters, consent decrees
Mutual recognition	EU–US MRA recognizes many inspection outcomes (with carve-outs)	FDA may rely on EU inspection data under the MRA; separate FDA inspection still possible
Annex system	Yes — numbered topic-specific annexes (sterile, biologicals, QP certification, computerised systems, etc.)	No annex system; guidance documents instead
Distribution (GDP)	EudraLex Vol. 4 GDP Guidelines (2013/C 343/01) — a distinct regime	No standalone GDP regulation; storage/distribution under Part 211
Food / supplements	Volume 4 broad + product-specific annexes	Separate CFR parts — 111 (supplements), 117 (food, FSMA)

The rest of this piece takes the rows that actually drive cost and inspection risk and unpacks them.

2. Two Architectures: Principle vs. Prescription

The most important thing to understand about EU GMP and FDA GMP is that they are built differently before they say anything about a single control.

FDA GMP is prescriptive and codified. 21 CFR Part 211 is law — binding regulation with the force of the Federal Food, Drug & Cosmetic Act behind it. It tells you, in numbered subparts, what records to keep, what a master production record must contain (211.186), how long to retain batch records (211.180), and that an out-of-specification result must be investigated (211.192). FDA elaborates expectations through guidance documents (Process Validation 2011, Aseptic Processing 2004, Data Integrity 2018), which are not binding but which inspectors apply as the current thinking.

EU GMP is principle-based and layered. The legal obligation lives in EU directives (the Union code, Directive 2001/83/EC; GMP principles in Commission Directive (EU) 2017/1572). The detail lives in EudraLex Volume 4 — Part I (finished products), Part II (active substances, ≈ ICH Q7), and a system of annexes that govern specific activities (sterile manufacture, biologicals, radiopharmaceuticals, QP certification, computerised systems, qualification & validation). Volume 4 is technically guidance, but Member State authorities treat conformance as the expectation, and an annex such as Annex 1 functions as a de facto requirement.

Why it matters operationally: an FDA-first operator tends to build documentation that maps directly to CFR citations — defensible, literal, sometimes rigid. An EU inspector asks whether your system embodies the principle, and will probe a control that is technically CFR-compliant but doesn't demonstrate quality-risk-management thinking. Building for both means writing controls that satisfy the prescriptive citation and demonstrate the principle. That dual posture is the core of the integrated build.

3. The Qualified Person — the Defining Difference

If you remember one thing from this comparison, remember the QP.

In the EU, no batch of a medicinal product may be released to market until a Qualified Person has certified it. The QP is a named, legally identified individual — qualified under Directive 2001/83/EC (Articles 48–52, with the eligibility criteria of Article 49) and operating under Annex 16. The QP personally attests that the batch was manufactured and tested in accordance with GMP and the marketing authorization. This is a personal legal accountability that attaches to a human being, not a department. For imported product, the QP additionally confirms that the batch meets EU requirements even though it was made elsewhere — which is why a US manufacturer exporting to the EU needs a QP in the importation chain, typically at the EU importer/site of certification.

In the US, there is no QP. 21 CFR 211.22 vests batch disposition in the quality control unit — an organizational function with authority to approve or reject components, in-process materials, and finished products. Release is an institutional decision, documented and signed, but it does not carry the personal statutory liability of QP certification.

The practical consequences for a dual-market operator:

You will need to identify and engage a QP (in-house or contracted) 12–18 months before your first EU shipment. QP services are a specialized, regulated function — not a title you assign internally.
Your batch-release SOP must support two disposition models: QC-unit release for the US market, QP certification for the EU market, with a clear control on which batches are in which stream.
The data package the QP needs (full batch genealogy, deviation closure, analytical results, supply-chain qualification, and for imports a confirmation of equivalence) must be assembled to a standard the QP will personally stand behind. Build the batch record to feed that package from day one.

No FDA-side construct substitutes for this. It is the cleanest example of why "FDA-compliant" and "EU-ready" are not the same statement.

4. The Pharmaceutical Quality System

EU: ICH Q10 is explicitly required. EudraLex Volume 4 Chapter 1 ("Pharmaceutical Quality System") obliges a documented, management-owned PQS with stated quality objectives, management review, knowledge management, and lifecycle coverage. The PQS is the umbrella; everything else hangs from it.

US: Part 211 mandates a quality control unit (211.22) and the elements of a quality system, and FDA's own guidance (Q10 was adopted as an FDA guidance) aligns with the PQS concept — but Part 211 does not independently command "thou shalt operate an ICH Q10 PQS." In practice, a modern FDA-inspected operation runs a Q10-style system anyway, because data-integrity and lifecycle expectations effectively require it.

The delta to build for: an EU inspector will look for the governing artifacts of a Q10 PQS — measurable quality objectives, a management-review cadence with documented decisions, a knowledge-management approach, and explicit lifecycle stages (development → transfer → commercial → discontinuation). A US-baseline operation often has the pieces but not the governing umbrella. Build the Q10 PQS as your top layer and you satisfy the EU explicitly and the US comfortably.

5. API Manufacturing — the Congruent Layer

Good news for once: at the active-substance layer the two systems converge almost completely. ICH Q7 is the GMP standard for active pharmaceutical ingredients, adopted by FDA as guidance and incorporated into EU GMP as EudraLex Volume 4 Part II. An operator who builds API manufacturing to ICH Q7 — API Starting Material determination, process validation, in-process controls, cleaning validation, the quality-unit release of each API batch, and a Q7-conformant Certificate of Analysis — is substantially aligned for both markets.

The residual deltas are at the edges: the EU expects the API to feed a QP-certified finished product, and EU importers of APIs have specific written-confirmation expectations for third-country active substances. But the manufacturing standard itself is shared. If you are sequencing an integrated build, the API layer is where dual compliance is least painful — anchor it on Q7 and move on.

6. Validation and Qualification

Both regimes require validated processes and qualified equipment over a lifecycle; they anchor the requirement differently.

EU — Annex 15 (Qualification and Validation). Prescribes the qualification lifecycle (DQ → IQ → OQ → PQ), process validation (traditional, continuous, or hybrid), cleaning validation, and ongoing process verification, with a Validation Master Plan as the governing document. Annex 15 is explicit and is read as a requirement.

US — 211.68/211.100/211.110 + FDA Process Validation Guidance (2011). The CFR requires validated processes; the 2011 guidance supplies the now-standard three-stage lifecycle: Stage 1 process design, Stage 2 process qualification (PPQ), Stage 3 continued process verification.

The delta: the vocabulary and document architecture differ (Annex 15's DQ/IQ/OQ/PQ + VMP vs. the FDA three-stage model), but the substance is highly compatible. Build a Validation Master Plan that maps both vocabularies — qualification lifecycle for the EU, the three stages for the FDA — and you run one validation program that speaks both languages. This is exactly the kind of "knowable, finite delta" the integrated build is designed to absorb.

7. Contamination Control and Sterile Manufacture

This is where the EU has pulled meaningfully ahead in explicitness.

EU — Annex 1 (revised 2022, in force August 2023). The revised Annex 1 makes a Contamination Control Strategy (CCS) mandatory: a documented, holistic strategy spanning facility design, utilities, personnel, process, and monitoring, justified by quality risk management. It also tightened expectations on barrier technology (RABS/isolators), environmental monitoring, and contamination control across sterile and — by principle — non-sterile operations.

US — 21 CFR 211.113 + FDA Aseptic Processing Guidance (2004). The CFR requires control of microbiological contamination and validation of sterilization processes; the 2004 aseptic guidance details facility classification, media fills, and environmental monitoring. FDA does not use the phrase "Contamination Control Strategy" as a named, mandatory artifact, though modern inspections increasingly expect equivalent thinking.

The delta to build for: if you are sterile (or aseptically processed), the EU's mandatory CCS is the higher bar — build it, and you cover the FDA expectations as a subset. Even for non-sterile operations, authoring a CCS-style document is the defensible move for a dual-market site. Allergen cross-contamination, notably, is handled US-side under the food rules (Part 117) rather than the drug CFR — a carve-out worth tracking if your site also runs food or supplement lines.

8. Deviations, OOS, and CAPA

Closely aligned, with a difference of emphasis.

Both require that deviations be investigated, root cause established, corrective and preventive action taken, and out-of-specification results formally investigated — the US codifies the OOS investigation explicitly at 21 CFR 211.192 (and FDA's 2006 OOS guidance details the laboratory-vs-manufacturing investigation phases). Both expect a CAPA system.

The EU places heavier visible weight on trending — the PQS expectation (Q10 / Volume 4 Chapter 1) that you analyze deviations, complaints, and quality data over time and feed the trends into management review and continual improvement. An FDA-baseline operation that closes deviations one-by-one but doesn't trend them is technically investigating yet will look thin to an EU inspector. Build trending and periodic product quality review into the system and both regimes are satisfied.

9. Supplier Qualification and the Supply Chain

US: 211.84 requires identity testing and qualification of components and the suppliers behind them; the quality unit owns approval. Quality agreements are expected (FDA's 2016 contract-manufacturing guidance), but the accountability sits with the internal QC unit.

EU: supplier qualification is reinforced by QP oversight and explicit written technical/quality agreements (Volume 4 Chapter 7, Outsourced Activities), and for active substances by importer confirmation obligations. The QP's personal certification means the QP has a direct interest in — and accountability for — the integrity of the supply chain feeding each batch.

The delta: the mechanics are similar (approved supplier list, audits, identity testing, quality agreements); the EU adds a layer of personal accountability through the QP and a firmer expectation of written quality agreements with every party that touches product quality. Build to the EU expectation — quality agreements with every supplier and contract partner, risk-based audits, and a supplier file the QP would sign off on — and the US requirement is met inside it.

10. Inspections and Enforcement

The two systems inspect and enforce through different machinery.

US — FDA. Conducts domestic and foreign inspections; documents findings on a Form 483; escalates through Warning Letters, import alerts, and ultimately consent decrees. FDA publishes much of this, and a Warning Letter is a public, reputationally significant event. Inspections are increasingly data-integrity-focused.

EU — national competent authorities. Inspections are conducted by Member State authorities (e.g., BfArM in Germany, ANSM in France, AIFA in Italy; the MHRA in the post-Brexit UK operates its own parallel regime). Outcomes feed the EudraGMDP database; a satisfactory inspection yields a GMP certificate, and a serious failure can produce a statement of non-compliance that propagates across the EU. There is no single "EU FDA" — you face the national authority of the supervising Member State.

The delta to build for: an EU GMP certificate is issued by a specific national authority and recognized EU-wide; a US facility selling into the EU is typically inspected by (or on behalf of) the competent authority of the importing Member State, unless an MRA pathway applies — which brings us to the next section.

11. Mutual Recognition — What the MRA Actually Does

The EU–US Mutual Recognition Agreement (the Pharmaceutical Annex, operational in stages from 2017 onward) lets the two sides rely on each other's inspection outcomes for many human medicinal products, reducing duplicate inspections. This is real and valuable — an FDA inspection can, in scope, satisfy an EU authority and vice versa.

But read the limits carefully:

It is recognition of inspections, not of all requirements. The MRA reduces duplicate inspections; it does not erase the QP requirement, the marketing-authorization obligations, or EU-specific labeling and pharmacovigilance duties.
Carve-outs remain. Vaccines and plasma-derived products sit outside the operational scope (as do human blood, tissue, and organs, and veterinary immunologicals). Investigational medicinal products are in scope, and veterinary pharmaceuticals were added to the MRA in 2023 — the carve-out list is narrower than it once was, so check the current scope rather than assuming a product class is excluded.
A separate inspection can still happen. Either authority retains the right to inspect, and for-cause inspections are unaffected.

The practical posture: treat the MRA as a possible efficiency, not a guarantee. Design for a full inspection by either authority; if the MRA spares you a duplicate, that's upside. Do not scope your quality system on the assumption that one inspection covers both markets.

12. The Annex System vs. Guidance Documents

The EU's defining structural feature is its numbered annex system — topic-specific annexes within Volume 4 covering sterile products (Annex 1), biological products, radiopharmaceuticals, qualification & validation (Annex 15), QP certification & batch release (Annex 16), computerised systems (Annex 11), reference and retention samples (Annex 19), and more. An annex is the EU's way of giving binding-in-practice detail to a category of activity.

The FDA has no annex system. The equivalent detail lives in guidance documents (Aseptic Processing, Process Validation, Data Integrity, Quality Metrics) and in compendial standards (USP). Guidance is formally non-binding but applied as current expectation.

Why it matters: when you map your quality system, the EU side maps to annexes and the US side maps to CFR citations + guidance. Build a cross-reference matrix — each control traced to the relevant annex and the relevant CFR/guidance — and your documentation answers either inspector in their own reference frame. That cross-reference matrix is, in practice, the connective tissue of an integrated EU/FDA build.

13. Distribution — GDP Is a Distinct EU Regime

A trap for US-centric operators: Good Distribution Practice is a separate, named regime in the EU and is not in the US.

EU: the GDP Guidelines (2013/C 343/01) govern the storage and distribution of medicinal products — wholesale-dealer authorization, a Responsible Person, temperature control and mapping, qualification of customers and suppliers, falsified-medicines safeguards, and transport validation. GDP is inspected and certified in its own right.

US: there is no standalone federal GDP regulation of the EU type. Storage and distribution sit under the relevant Part 211 provisions (e.g., 211.142 warehousing, 211.150 distribution procedures) and, for supply-chain security, the Drug Supply Chain Security Act (DSCSA) — which is a serialization/traceability regime, not a GDP analog.

The delta to build for: if you distribute into the EU, you need a GDP-conformant distribution quality system in addition to your manufacturing GMP — Responsible Person, temperature mapping, validated transport. A US distribution setup built only to Part 211 + DSCSA will not satisfy EU GDP. Scope it separately.

14. Food and Dietary Supplements — Where the Frameworks Diverge Most

For operators outside the classic drug lane — including many cannabis and botanical manufacturers — this row matters most.

US: food and dietary supplements are carved into separate CFR parts. 21 CFR Part 111 is the cGMP for dietary supplements; 21 CFR Part 117 is the FSMA cGMP + Hazard Analysis and Risk-Based Preventive Controls for human food. These are distinct from the drug cGMP of Part 211, with their own structures (e.g., Part 117's preventive-controls and PCQI requirements).

EU: there is no single "EU Part 111/117." GMP for medicinal products applies broadly under Volume 4 with product-specific annexes; food and food supplements are regulated under separate EU food law (general food hygiene under Regulation (EC) 852/2004 and the food-supplements framework under Directive 2002/46/EC), not under the medicinal-products GMP system.

Why it matters for cannabis/botanicals: a US operator running to Part 111 (supplement) or Part 117 (food) as their behavioral baseline is structurally below pharmaceutical GMP. Moving such an operation toward EU medicinal-product export is not an enhancement of the food/supplement system — it is a near-rebuild onto Volume 4 (with GACP/Annex 7 at the cultivation/herbal layer). Know which lane you are actually in before you scope the build. (We unpack the cannabis-specific version of this in Build Once, Build to the Highest Bar.)

15. Practical Implications — Building for Both

The recurring theme is the strategic thesis of Build Once, Build to the Highest Bar: do not build two quality systems. Build one, to the highest common bar, with explicit hooks for the deltas. Concretely:

Top layer: an ICH Q10 PQS — satisfies the EU explicitly, the US comfortably.
Batch release: dual-path — QC-unit release (US) + QP certification (EU) — engineered into one batch-release SOP, with the QP engaged 12–18 months ahead.
Validation: one Validation Master Plan that speaks both Annex 15 (DQ/IQ/OQ/PQ) and the FDA three-stage model.
Contamination control: author the CCS to the EU Annex 1 bar; it covers the FDA expectations as a subset.
Documentation: a cross-reference matrix tying each control to the EU annex and the CFR/guidance citation; add a Site Master File (EU expectation) on top of your US record architecture.
Distribution: if you ship to the EU, a separate GDP quality system with a Responsible Person.
Quality agreements & trending: build to the EU expectation (written agreements with every quality-relevant partner; documented trending into management review) and the US requirement sits inside it.

Sequential, market-by-market builds — "FDA now, EU later" — routinely cost more than the integrated approach, because operators rewrite master records, re-validate, re-qualify suppliers, and re-train. Build once.

16. What This Piece Is and Is Not

This piece is a clause-level orientation to where EU GMP (EudraLex Volume 4) and FDA GMP (21 CFR 210/211, plus Parts 111/117) converge and diverge, written for operators building to supply both markets. It is the map of the deltas.

This piece is not an implementation guide, a marketing-authorization or NDA strategy, or QP-engagement advice. It does not substitute for the EudraLex and CFR primary texts, and it does not cover the marketing-authorization, pharmacovigilance, or labeling obligations that sit alongside GMP. The integrated build framework is in Build Once, Build to the Highest Bar; the risk-based method that scopes any such build is in One Pathway, Every Regulator.

This piece is not legal or regulatory-affairs advice. Confirm current requirements — particularly the EU legal-basis instruments, GDP guideline, and MRA scope — against the primary sources with qualified counsel before acting.

Next Steps for Your Operation

If you are weighing an EU export lane — or you are already FDA-compliant and want to know what the EU adds — the first move is a gap assessment against the integrated EU/FDA bar, not a guess about which deltas matter. The QP timeline alone (12–18 months) means the diagnostic should happen early.

Intrepid Scientific offers two starting points:

1. EU GACP + GMP Gap Assessment (Export Readiness) — from $10,000 remote. A scoped Stage 1 assessment that maps cultivation (GACP) and manufacturing (EU GMP Part I & II) against the EU export bar, identifies the deltas that gate export (the QP, Annex 1 CCS, the Site Master File, Annex 15 validation, EU GDP), and delivers a sequenced remediation roadmap — with the QP timeline on the critical path — plus a binding Stage 2 recommendation. Phased and decision-gated; either party may exit after Stage 1.

2. Integrated PQS Build. Full implementation of the one-system-to-the-highest-bar approach — Q10 PQS, dual batch-release architecture, Annex 15 / FDA three-stage validation, Annex 1 CCS, the EU/CFR cross-reference matrix, Site Master File, and QP-function design for EU release.

Talk to us about a gap assessment →

Read the integrated-build framework →

Run the method on your own operation — the Risk Assessment Worksheet →

Authorities and Source Standards

European Union

EudraLex Volume 4 — EU Guidelines for GMP for Medicinal Products for Human and Veterinary Use (Part I, Part II, and annexes)
Directive 2001/83/EC — the Union code relating to medicinal products for human use (QP at Arts. 48–52)
Commission Directive (EU) 2017/1572 — GMP principles for human medicinal products (replacing Directive 2003/94/EC)
Delegated Regulation (EU) 2017/1569 — GMP for investigational medicinal products
EudraLex Vol. 4 Annex 1 (sterile, rev. 2022), Annex 11 (computerised systems), Annex 15 (qualification & validation), Annex 16 (QP certification & batch release), Annex 19 (reference & retention samples), Chapter 1 (PQS), Chapter 7 (outsourced activities)
GDP Guidelines (2013/C 343/01); Falsified Medicines Directive 2011/62/EU

United States

21 CFR Parts 210 & 211 — cGMP for finished pharmaceuticals (incl. 211.22 QC unit, 211.84 components, 211.113 contamination, 211.180/186 records, 211.192 OOS)
21 CFR Part 111 — cGMP for dietary supplements
21 CFR Part 117 — cGMP + Hazard Analysis and Risk-Based Preventive Controls for human food (FSMA)
FDA Process Validation Guidance (2011); Aseptic Processing Guidance (2004); OOS Guidance (2006); Data Integrity Guidance (2018); Contract Manufacturing Quality Agreements Guidance (2016)
Drug Supply Chain Security Act (DSCSA)

International

ICH Q7 (APIs) · Q9(R1) (Quality Risk Management) · Q10 (Pharmaceutical Quality System)
EU–US Mutual Recognition Agreement, Pharmaceutical Annex

About the Authors

Andrew Samann is a Cofounder of Intrepid Scientific. Recognized as a Processing Pro on The Cannabis Scientist's Power List for 2021 and 2022, Andrew has led over 100 GMP and quality-system engagements across North America, South America, and the European Union — including international compliance work against FDA, EU GMP, EMA, Australian TGO, and ICH guidelines. He led the ASTM D37.02 Quality Management Systems Subcommittee for Cannabis, has certified multiple Canadian cannabis Licensed Producers, and is also Founder & CEO of Orion GMP Solutions.

Kate Evans, PhD is a Cofounder of Intrepid Scientific and principal of Longboard Scientific Consulting Corporation. She holds a PhD in analytical chemistry / pharmaceutical analysis and serves as a lead assessor for both ANAB and A2LA under ISO/IEC 17025. She is the Technical Contact for ASTM D8493-23 (cannabis/hemp sample preparation) and a technical consultant to the ASTM proficiency-testing program. Her pharmaceutical-analysis (cGMP) work spans analytical method development and validation, instrument qualification, and FDA test-method submission, alongside expert-witness testimony in cannabis and hemp testing and manufacturing.

About Intrepid Scientific

Intrepid Scientific is an independent scientific consulting firm offering ISO/IEC 17025 lab accreditation readiness, GMP and cGMP compliance, analytical method development and validation, microbiology and environmental monitoring, expert witness, and Federal Pathway / Schedule III advisory across cannabis, hemp, food and beverage, pharmaceutical, and dietary-supplement industries. Senior scientists. Direct engagement.

Cofounders: Andrew Samann; Kate Evans, PhD; Tess Eidem, PhD; Julie Kowalski, PhD.

Learn more at intrepidscientific.com.